Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.

PURPOSE To investigate further the safety and efficacy of the sirolimus-eluting S. M.A.R.T. Nitinol Self-expanding Stent by comparison with a bare stent in superficial femoral artery (SFA) obstructions. MATERIALS AND METHODS This randomized, double-blind study involved 57 patients (29 in the sirolimus-eluting stent group and 28 in the bare stent group) with chronic limb ischemia and SFA occlusions (66.7%) or stenoses (average lesion length, 81.5 mm +/- 41.2). Stent implantation followed standard interventional techniques and a maximum of two stents could be implanted. The primary endpoint was the in-stent mean lumen diameter at 6 months as determined by quantitative angiography. RESULTS Both stent types were effective in revascularizing the diseased SFA and allowing sustained patency for at least 6 months. There was no statistically significant difference between treatment groups in the in-stent mean lumen diameter at 6 months (4.94 mm +/- 0.69 and 4.76 mm +/- 0.54 mm for sirolimus-eluting and bare stent groups, respectively; P = .31). Although the diameter of the target lesion tended to be larger and percent stenosis tended to be lower with the sirolimus-eluting stent, there were no statistically significant differences between treatments in terms of any of the variables. The mean late loss values were 0.38 mm +/- 0.64 and 0.68 mm +/- 0.97 for the sirolimus-eluting stent group and the bare stent group, respectively (P = .20). The binary restenosis rates, with a cutoff of 50% at 6 months, were zero in the sirolimus-eluting stent group and 7.7% in the bare stent group (P = .49). Clinical outcomes matched angiographic outcomes with improvements in ankle-brachial index and symptoms of claudication. There was no significant difference between treatments in terms of adverse events. CONCLUSION Although there is a trend for greater efficacy in the sirolimus-eluting stent group, there were no statistically significant differences in any of the variables.

[1]  J. Brossmann,et al.  Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. , 2002, Journal of vascular and interventional radiology : JVIR.

[2]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[3]  J. Olin,et al.  High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. , 1997, Journal of vascular surgery.

[4]  Gerhard Ziemer,et al.  Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results , 2002, Circulation.

[5]  J. Wiskirchen,et al.  Drug-eluting stents: potential applications for peripheral arterial occlusive disease. , 2003, Journal of vascular and interventional radiology : JVIR.

[6]  E. Diethrich,et al.  Multicenter trial of the wallstent in the iliac and femoral arteries. , 1995, Journal of vascular and interventional radiology : JVIR.

[7]  S. Cheng,et al.  Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis. , 2001, Cardiovascular surgery.

[8]  B. Walpoth,et al.  A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions , 1992, CardioVascular and Interventional Radiology.

[9]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[10]  Stephan H. Duda,et al.  Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease , 2003 .

[11]  J. Brossmann,et al.  Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. , 2001, Journal of vascular and interventional radiology : JVIR.

[12]  R. Rutherford,et al.  Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. , 1991, Journal of vascular and interventional radiology : JVIR.

[13]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[14]  Deepak L. Bhatt,et al.  Superficial femoral artery occlusion: nitinol stents achieve better flow and reduce the need for medications than balloon angioplasty alone. , 2003, The Journal of invasive cardiology.